文献速递银屑病与炎症性皮肤病

PA2G4促进银屑病角质形成细胞增殖与存活

Proliferation-associated protein 2G4 promotes keratinocyte proliferation and survival in psoriasis.
PubMed 文献 · Br J Dermatol · 2026-01-01

该研究通过bulk、单细胞和空间RNA测序及免疫组化,发现PA2G4在银屑病皮损中高表达且主要局限于基底层增殖性角质形成细胞,其表达与疾病严重程度、棘层肥厚和中性粒细胞浸润正相关。在原代角质形成细胞和重建人表皮模型中,CRISPR/Cas9敲除PA2G4或使用小分子抑制剂WS6可抑制增殖、促进分化并导致细胞死亡,提示抑制PA2G4可能成为银屑病新治疗选择。

要点

  • PA2G4在银屑病皮损中高表达且与疾病严重程度正相关
  • 敲除PA2G4可抑制角质形成细胞增殖并促进分化
  • 小分子抑制剂WS6可下调增殖与存活相关基因

核心结论

  • PA2G4可促进银屑病角质形成细胞过度增殖和存活,从而关键性影响表皮稳态。
  • 抑制PA2G4可能代表银屑病的一种新治疗选择。

研究设计与样本

  • 采用bulk、单细胞和空间RNA测序联合免疫组化比较银屑病皮损与非皮损对照中PA2G4表达。
  • 在原代人类角质形成细胞和重建人表皮(RHE)模型中,通过CRISPR/Cas9介导的PA2G4敲除和小分子抑制剂WS6药理抑制进行功能研究。
  • 使用RNAseq、Western blot、划痕实验和annexin V染色研究PA2G4对增殖、分化和存活的调控作用。

主要发现

  • PA2G4在银屑病中高度丰富,其表达主要局限于基底层增殖性角质形成细胞。
  • PA2G4表达与银屑病严重程度、棘层肥厚程度、中性粒细胞浸润及银屑病上调基因正相关。
  • 原代人类角质形成细胞中PA2G4敲除激活分化通路而抑制增殖通路,导致增殖和炎症相关基因(如MKI67、IL20、VEGFA和HIF1A)下调,分化与细胞黏附标志物(如KRT6C、LCE2C和DSG4)上调。
  • PA2G4敲除在划痕实验中减少角质形成细胞增殖,在RHE模型中减弱白介素-22诱导的棘层肥厚,并促进角质形成细胞死亡。
  • 使用小分子抑制剂WS6药理抑制PA2G4同样下调与增殖和细胞存活相关的基因。

临床怎么用

  • PA2G4表达水平与银屑病严重程度正相关,可能作为反映疾病活动度的潜在生物标志物。
  • 抑制PA2G4(如通过小分子抑制剂WS6)可抑制角质形成细胞增殖并促进分化,提示其作为银屑病治疗靶点的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is a noncommunicable inflammatory skin disease that affects approximately 2-3% of the world's population. Given its high impact on quality of life and the fact that a subset of patients exhibits suboptimal or secondary loss of response to current treatments, identifying new therapeutic strategies is crucial. Proliferation-associated protein 2G4 (PA2G4) is a transcription factor that has been exclusively studied in cancer research, where it promotes cell growth and enhances tumorigenesis by inhibiting apoptosis. However, its role in inflammatory skin diseases remains largely unknown. OBJECTIVES: To elucidate the pathophysiological and immunological functions of PA2G4 in psoriasis, and to evaluate its potential as a therapeutic target. METHODS: Bulk, single-cell and spatial RNA sequencing (RNAseq) combined with immunohistochemistry were used to assess PA2G4 expression in psoriatic skin compared with nonlesional control samples. Functional studies were performed in primary human keratinocytes and reconstructed human epidermis (RHE) models using the CRISPR/Cas9-mediated knockout of PA2G4 and pharmacological inhibition of PA2G4 with the small-molecule inhibitor WS6. The regulatory effects of PA2G4 on cellular processes, such as proliferation, differentiation and survival, were investigated using RNAseq, Western blot analysis, scratch assays and annexin V staining. RESULTS: PA2G4 was highly abundant in psoriasis, and its expression was predominantly restricted to basal proliferating keratinocytes. Its expression was positively correlated with psoriasis severity, the degree of acanthosis, neutrophil infiltration and genes that are upregulated in psoriasis. PA2G4 knockout in primary human keratinocytes activated differentiation pathways while suppressing proliferation pathways, resulting in the downregulation of proliferation- and inflammation-related genes (e.g. MKI67, IL20, VEGFA and HIF1A) and the upregulation of differentiation and cell adhesion markers (e.g. KRT6C, LCE2C and DSG4). Functionally, PA2G4 knockout reduced keratinocyte proliferation in scratch assays, attenuated interleukin-22-induced acanthosis in RHE models and promoted keratinocyte death. Pharmacological inhibition of PA2G4 using the small-molecule inhibitor WS6 similarly downregulated genes associated with proliferation and cell survival. CONCLUSIONS: PA2G4 could promote keratinocyte hyperproliferation and survival in psoriasis, thereby critically influencing epidermal homeostasis. Therefore, inhibition of PA2G4 may represent a new treatment option for psoriasis. Psoriasis (pronounced ‘suh-rye-uh-sis’) is an inflammatory skin disease. It affects 2% to 3% of people worldwide. People with the disease have raised, scaly patches of skin all over the body. These symptoms are caused by excessive growth of skin cells and a decrease in dying skin cells. Immune cells are also involved. A few therapies work well in treating the disease. These treatments mainly target the immune cells in skin. However, they can stop working or do not work enough in some people. We investigated the role of a protein called PA2G4 in psoriasis. PA2G4 increases the growth and progression of several cancerous tumours. Tumours share key features with psoriasis, including excessive growth and reduced cell death. We collected skin samples donated by people with psoriasis. Then, we used advanced laboratory techniques to analyse where and how much PA2G4 is produced in psoriasis compared with healthy skin. We found high levels of PA2G4 in skin samples from people with psoriasis compared with healthy donors. This was related to how severe their disease was. We were also able to identify skin cells as main producers of PA2G4. Next, we compared skin cells with normal and no levels of PA2G4. We found that a lack of PA2G4 resulted in lower levels of cell growth and inflammation. In addition, genes related to a process called cell differentiation (where a cell changes from a general, unspecialized form to a cell capable of carrying out a specific function) were found at higher levels. Finally, we looked at cell growth. We found that skin cells without PA2G4 had less ability to grow and reduced skin thickening, and did not die as often. Our results highlight the role of PA2G4 in the development and progression of psoriasis. We suggest that inhibiting PA2G4 may be a possible new treatment option for people with psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Raunegger T, Wasserer S, Eigemann J, et al. Proliferation-associated protein 2G4 promotes keratinocyte proliferation and survival in psoriasis. Br J Dermatol. 2026. PMID: 42008715. doi:10.1093/bjd/ljag154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。